STAAR Surgical reported net sales of $42.6 million for the first quarter of 2025, a 45% decrease year-over-year, primarily due to a planned reduction of channel inventory in China. The company incurred a net loss of $(54.2) million and an adjusted EBITDA loss of $(26.4) million. Despite the challenges in China, sales excluding China increased by 9% year-over-year.

STAAR Surgical experienced a challenging fourth quarter in 2024, with net sales significantly decreasing to $49.0 million from $76.3 million in the prior year quarter. This decline was largely driven by a substantial drop in China revenue. The company reported a net loss of $(34.2) million, or $(0.69) per diluted share, a significant shift from a net income of $7.8 million in the same period last year. Despite strong performance outside of China, the overall results were heavily impacted by the weak Chinese market.

STAAR Surgical reported a 10% increase in net sales to $88.6 million for Q3 2024, driven by ICL sales growth and unit growth. Net income increased to $10.0 million, or $0.20 per share.

STAAR Surgical reported a 7% increase in net sales to $99.0 million for Q2 2024, with ICL sales up 7% and units up 3%. The company's gross margin improved to 79.2%, and net income rose to $7.4 million, or $0.15 per share. STAAR Surgical raised its full-year outlook for net sales to $340 million - $345 million and adjusted EBITDA to approximately $42 million.

STAAR Surgical reported a 5% increase in net sales to $77.4 million in Q1 2024, with ICL sales up by 9%. The company experienced a net loss of $3.3 million, or $0.07 per share, compared to a net income of $2.7 million, or $0.05 per share in the prior year quarter. The company reiterated its fiscal year 2024 net sales outlook of $335 million to $340 million and increased Adjusted EBITDA outlook to approximately $39 million.

STAAR Surgical reported a 19% increase in net sales to $76.3 million for the fourth quarter of 2023, driven by a 22% increase in ICL sales. Net income increased to $7.8 million, or $0.16 per share. The company affirmed its fiscal year 2024 net sales outlook of $335 million to $340 million.

STAAR Surgical reported net sales of $80.3 million, a 6% increase year-over-year, driven by a 13% increase in ICL sales. The company's ICL sales growth outperformed industry procedure growth, except in China. Due to global economic uncertainty, the company expects fiscal 2023 ICL sales to be at the low end of the previously provided range of $320 million to $325 million.

STAAR Surgical reported a 14% increase in net sales to $92.3 million, driven by a 19% increase in ICL sales. However, net income decreased to $6.1 million, or $0.12 per diluted share, due to higher operating expenses and accounting adjustments related to the Other Products segment. The company is updating its fiscal 2023 ICL sales outlook to a range of approximately $320 million to $325 million.

STAAR Surgical reported a 16% increase in net sales to $73.5 million for Q1 2023, with ICL sales driving growth. The company raised its fiscal year 2023 net sales outlook to $348 million, reflecting confidence in accelerating sales momentum.

STAAR Surgical reported a 9% increase in net sales to $64.0 million for Q4 2022, driven by a 15% increase in ICL sales and a 20% increase in ICL unit growth. The company's net income increased to $0.12 per share, and they reaffirmed their outlook for strong growth in 2023.

STAAR Surgical Company reported net sales of $76.0 million for the third quarter of 2022, a 30% increase compared to the prior year quarter. ICL sales increased by 33% and ICL unit growth was 40%. Net income was $10.3 million, or $0.21 per diluted share, compared to $6.0 million, or $0.12 per diluted share, for the prior year quarter.

STAAR Surgical reported record second-quarter net sales of $81.1 million, a 30% increase year-over-year, driven by a 32% increase in ICL sales and a 42% increase in ICL unit growth. The company reaffirmed its fiscal year 2022 net sales outlook of approximately $295 million.

STAAR Surgical reported record first-quarter net sales of $63.2 million, a 25% increase year-over-year. ICL sales grew by 26%, with unit growth up by 29%. The company reaffirmed its fiscal year 2022 net sales outlook of approximately $295 million, representing a 28% year-over-year growth.

STAAR Surgical reported a strong fourth quarter in 2021, with net sales increasing by 28% to $59.0 million, driven by a 33% increase in ICL sales. The company's gross margin improved to 76.3%, and net income per share rose to $0.10. The company reaffirms its previously provided outlook for Net sales of approximately $295 million for fiscal 2022.

STAAR Surgical reported a strong third quarter with net sales of $58.4 million, a 24% increase year-over-year. ICL sales drove growth, increasing 31% year-over-year. The company raised its full-year 2021 net sales outlook to $230 million to $231 million.

STAAR Surgical reported record second-quarter net sales of $62.4 million, a 77% increase year-over-year, driven by ICL sales growth of 93%. The company raised its full-year net sales outlook to a range of $227 million to $230 million.

STAAR Surgical reported net sales of $35.2 million, an 8% increase compared to the prior year quarter. ICL sales increased by 6% and units by 9%. Gross margin decreased to 70.4% from 74.2% in the prior year, and the company experienced a net loss of approximately breakeven per share, compared to a net income of $0.03 per share in the prior year quarter. Cash and cash equivalents ended the quarter at $110.9 million.